Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BAY W 6228; Baycol; Certa; Cervasta; Cholstat; Lipobay; Liposterol; Micro®; Rivastatin; Selta; Staltor; Stativa™; Vaslip; Zenas Micro

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Developer Bayer; Chiesi; Ferrer; Fournier Pharma; Fournier Pharma Inc; GSK; Laboratorios Vita
  • Class Antihyperlipidaemics; Pyridines
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia; Low HDL cholesterol

Most Recent Events

  • 24 Apr 2003 Groupe Fournier is now called Fournier Pharma
  • 23 Aug 2001 Withdrawn for Hypercholesterolaemia in Japan (PO)
  • 09 Aug 2001 Bayer has withdrawn cerivastatin worldwide except in Japan
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top